Radiomedix Inc.

Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map

BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025

Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more

The clinical data available for lead-212 provides initial proof-of-concept for its efficacy and safety in radioligand therapies for cancer

Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212 

The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto

The manufacturing-focused radiopharma met its primary endpoint but fell short of Novartis on rPFS; both companies face the same OS challenge

Target, ligand and radioisotope choices fuel the growing field